fda tirzepatide compounding warning 2024 2025 Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs, and a Pharmacy Operating Without Control Beware of Compounded Tirzepatide
Description
Tirzepatide has been associated with an increased risk of gallbladder adverse events, including cholelithiasis and cholecystitis
Changes in the appearance of the vaginal area and vulva tend to come with time it is common for the vagina to look different thinner
Foundayo will be the second oral GLP-1 drug available to consumers, after competitor Novo Nordisk introduced its Wegovy pill in January
Mounjaro isnt approved for use in people with type 1 diabetes
Tirzepatide follows its 2.5 mg to 15 mg escalation
